No single marker is sufficient to definitively identify senescent cells.
Thirty years after a single protein marker opened a window into cellular aging, science has arrived at a richer and more consequential understanding: the cells that stop dividing do not simply fade away, but linger as active agents of inflammation and tissue decay. A new review from Tufts University traces this arc from the 1995 discovery of senescence-associated beta-galactosidase to today's emerging therapies designed to eliminate or silence these cells. What began as a marker has become a mechanism — and a target.
- Senescent cells accumulate silently in aging tissues, releasing inflammatory signals that erode the body from within — not through absence, but through relentless, misdirected activity.
- No single biomarker can reliably identify these cells, forcing researchers to triangulate across multiple hallmarks and creating persistent ambiguity at the heart of the field.
- New technologies — single-cell sequencing, multi-omics, advanced imaging — are finally giving scientists the resolution to see senescence in its full diversity across tissues and disease states.
- Senolytic drugs designed to selectively clear senescent cells are shifting the field from observation to intervention, recasting aging not as inevitable decline but as a potentially treatable condition.
- The review makes clear that while understanding has advanced enormously, the complexity of senescent cell signaling and the risks of unintended harm mean the hardest questions are still open.
Thirty years ago, the identification of a protein called senescence-associated beta-galactosidase gave scientists their first reliable window into a hidden world of aging cells. A new review in the journal Aging, led by Chisaka Kuehnemann and Christopher D. Wiley of Tufts University, takes stock of what that discovery has since unlocked.
Cellular senescence, it turns out, is not a quiet retirement. Cells that stop dividing in response to stress or damage do not die — they persist, metabolically active, releasing a steady stream of inflammatory and signaling molecules into surrounding tissue. This secretory behavior, known as the SASP, accumulates over time and appears to drive the chronic inflammation and tissue dysfunction at the core of age-related disease. The cells do not stop working; they work against their neighbors.
Identifying senescent cells remains genuinely difficult. Biomarkers like p16, p21, and beta-galactosidase each capture part of the picture, but none is definitive alone. Senescence shares features with other biological states, and the cells themselves vary considerably across tissues and conditions — a complexity that early research did not anticipate.
New tools have transformed the field. Single-cell sequencing, multi-omics platforms, and computational analysis now allow researchers to map senescent cell communication at a granularity once unimaginable, tracing how these cells reshape inflammation, fibrosis, and tissue remodeling throughout the body.
The most consequential shift has been conceptual: senescent cells are no longer merely markers of aging but recognized drivers of disease. Senolytic therapies — designed to selectively eliminate these cells or suppress their harmful signals — have moved the field from description toward treatment. Thirty years on, the work is far from finished, but the direction is unmistakable: from a single marker to an entire ecosystem, and from observation to intervention.
Thirty years ago, a discovery changed how scientists think about aging. In 1995, researchers identified a marker called senescence-associated beta-galactosidase—a protein that appeared in cells that had stopped dividing. It was a key, and it unlocked a door that had been closed for decades. Now, three decades later, a new review published in the journal Aging takes stock of what that discovery has led to, and the answer is: a fundamental reimagining of how our bodies age.
The review, led by Chisaka Kuehnemann and Christopher D. Wiley of Tufts University, examines the evolution of senescence research from that first marker to today's sophisticated understanding of what happens when cells age. Cellular senescence, it turns out, is not simply a passive state of decline. Senescent cells are cells that have stopped dividing in response to stress or damage, yet they do not die. Instead, they remain metabolically active—busy, in their own way—and they release a steady stream of signaling molecules into the tissues around them. Over time, as these cells accumulate, they appear to drive chronic inflammation, tissue dysfunction, and the cascade of degenerative conditions we associate with getting older.
What makes senescent cells so consequential is not that they stop working, but that they keep working in ways that harm their neighbors. The review identifies multiple hallmarks now recognized as signatures of senescence: the stable halt in cell division, increased activity in lysosomes (the cell's recycling centers), the secretion of inflammatory and signaling molecules collectively called the senescence-associated secretory phenotype, or SASP, mitochondrial dysfunction, changes in the structure of the cell nucleus, accumulation of metals and lipofuscin (a cellular waste product), and a paradoxical resistance to stress that would normally trigger cell death. Each of these features tells part of the story of what a senescent cell is.
Yet identifying these cells remains surprisingly difficult. Researchers have developed biomarkers—p16, p21, and the original beta-galactosidase among them—but none of these markers is sufficient on its own. Many of the features associated with senescence can appear in other biological contexts, making it necessary to look at multiple characteristics simultaneously to confirm that a cell is truly senescent. This ambiguity has created both a challenge and an opportunity. It means that senescent cells are far more diverse than early research suggested, varying across different tissues and disease states in ways that are only now becoming clear.
The field has been transformed by new technologies. Single-cell sequencing, multi-omics approaches, advanced imaging, and computational analysis have given researchers tools to see senescence at a granularity that was impossible thirty years ago. They can now watch how senescent cells communicate with their environment through cytokines, extracellular vesicles, growth factors, and lipid mediators—a conversation that influences inflammation, tissue remodeling, fibrosis, and the aging-related dysfunction that ripples through the body.
Perhaps the most significant shift in thinking has come from the development of senolytic therapies—drugs designed to selectively eliminate senescent cells—and interventions that suppress the harmful signaling these cells produce. These advances have moved senescence from the category of a marker of aging to the category of an active driver of disease. Senescent cells are no longer simply a sign that aging is happening; they are now understood as a cause of aging-related illness, a distinction that opens the door to new treatments.
Thirty years after that first discovery, the field continues to expand. The review offers a comprehensive accounting of how far understanding has come, but it also makes clear that the work is far from finished. The diversity of senescent cells, the complexity of their signaling, and the challenge of targeting them without causing unintended harm all remain open questions. Yet the trajectory is clear: senescence research has moved from identifying a single marker to mapping an entire ecosystem of cellular dysfunction, and from observation to intervention.
Citas Notables
Senescent cells are remarkably diverse, creating challenges for researchers trying to identify and target them while also opening new opportunities for therapeutic development.— Kuehnemann and Wiley, Tufts University
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that senescent cells keep working even after they stop dividing? Why not just die?
Because they don't die quietly. They stay metabolically active and release inflammatory signals into the surrounding tissue. Over decades, as these cells accumulate, those signals add up. They're like a conversation that never ends, and the conversation is about damage and stress.
So the problem isn't the senescent cells themselves—it's what they're saying to their neighbors?
Exactly. The cells themselves are stuck, unable to divide. But they're broadcasting signals that trigger inflammation, tissue remodeling, fibrosis. They're influencing the health of the tissue around them in ways that contribute to aging and disease.
If we can identify these cells now, why is it still hard to know which ones are actually senescent?
Because senescence isn't a single state. Multiple features can appear in other contexts too. You need to see the whole picture—the arrest in division, the lysosomal activity, the mitochondrial dysfunction, the secretory profile. No single marker is enough.
That sounds like it would make treatment impossible. How do you target something so varied?
That's the frontier. New technologies like single-cell sequencing let researchers see how senescence varies across tissues and disease states. Once you understand the diversity, you can start thinking about which cells to target and how.
And senolytic therapies—drugs that kill senescent cells—they're already being tested?
Yes. The fact that these therapies exist, and that they show promise, has changed how scientists think about senescence. It's no longer just a marker of aging. It's something you can intervene on, something you can treat.
What happens in the next thirty years?
That's the question the field is asking now. The tools are better. The understanding is deeper. But senescent cells are remarkably diverse, and they're woven into aging in ways we're still untangling.